Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Mai 2018 10:00 ET | Quelle: ILiAD Biotechnologies, LLC

NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University

WESTON, Fla. and NASHVILLE, Tenn., May 15, 2018 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) and Vanderbilt University Medical Center today announced filing of an Investigational New Drug...
05. Juli 2017 09:00 ET | Quelle: ILiAD Biotechnologies, LLC

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical...
19. Februar 2016 09:55 ET | Quelle: ILiAD Biotechnologies, LLC

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups

NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...